Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration

Biology Open

Volumn 2, Issue 8, 2013, Pages 761-770

  Holmström, Kira M ^a   Baird, Liam ^b   Zhang, Ying ^b   Hargreaves, Iain ^c   Chalasani, Annapurna ^c   Land, John M ^c   Stanyer, Lee ^a   Yamamoto, Masayuki ^d   Dinkova Kostova, Albena T ^b,e   Abramov, Andrey Y ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c National Hospital   (United Kingdom)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Energy metabolism; Keap1; Mitochondria; Nrf2; Oxidative phosphorylation

Indexed keywords

EID: 84964999321     PISSN: None     EISSN: 20466390     Source Type: Journal    
DOI: 10.1242/bio.20134853     Document Type: Article

References (46)

1. Abramov, A. Y. and Duchen, M. R. (2010). Impaired mitochondrial bioenergetics determines glutamate-induced delayed calcium deregulation in neurons. Biochim. Biophys. Acta 1800, 297-304.
2. Abramov, A. Y., Smulders-Srinivasan, T. K., Kirby, D. M., Acin-Perez, R., Enriquez, J. A., Lightowlers, R. N., Duchen, M. R. and Turnbull, D. M. (2010). Mechanism of neurodegeneration of neurons with mitochondrial DNA mutations. Brain 133, 797-807.
3. Baird, L. and Dinkova-Kostova, A. T. (2011). The cytoprotective role of the Keap1-Nrf2 pathway. Arch. Toxicol. 85, 241-272.
4. Burchell, V. S., Gandhi, S., Deas, E., Wood, N. W., Abramov, A. Y. and Plun-Favreau, H. (2010). Targeting mitochondrial dysfunction in neurodegenerative disease: Part I. Expert Opin. Ther. Targets 14, 369-385.
5. Calkins, M. J., Johnson, D. A., Townsend, J. A., Vargas, M. R., Dowell, J. A., Williamson, T. P., Kraft, A. D., Lee, J. M., Li, J. and Johnson, J. A. (2009). The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid. Redox Signal. 11, 497-508.
6. Chance, B. and Williams, G. R. (1955). Respiratory enzymes in oxidative phosphorylation. I. Kinetics of oxygen utilization. J. Biol. Chem. 217, 383-393.
7. Crunkhorn, S. (2012). Deal watch: Abbott boosts investment in NRF2 activators for reducing oxidative stress. Nat. Rev. Drug Discov. 11, 96.
8. De Nicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S. et al. (2011). Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106-109.
9. Domijan, A. M. and Abramov, A. Y. (2011). Fumonisin B1 inhibits mitochondrial respiration and deregulates calcium homeostasis - implication to mechanism of cell toxicity. Int. J. Biochem. Cell Biol. 43, 897-904.
10. Duchen, M. R. (2004). Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol. Aspects Med. 25, 365-451.
11. Gandhi, S., Wood-Kaczmar, A., Yao, Z., Plun-Favreau, H., Deas, E., Klupsch, K., Downward, J., Latchman, D. S., Tabrizi, S. J., Wood, N. W. et al. (2009). PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol. Cell 33, 627-638.
12. Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I. et al.; DEFINE Study Investigators. (2012). Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367, 1098-1107.
13. Greco, T., Shafer, J. and Fiskum, G. (2011). Sulforaphane inhibits mitochondrial permeability transition and oxidative stress. Free Radic. Biol. Med. 51, 2164-2171.
14. Habig, W. H. and Jakoby, W. B. (1981). Glutathione S-transferases (rat and human). Methods Enzymol. 77, 218-231.
15. Hargreaves, I. P., Heales, S. J. and Land, J. M. (1999). Mitochondrial respiratory chain defects are not accompanied by an increase in the activities of lactate dehydrogenase or manganese superoxide dismutase in paediatric skeletal muscle biopsies. J. Inherit. Metab. Dis. 22, 925-931.
16. Hayes, J. D., McMahon, M., Chowdhry, S. and Dinkova-Kostova, A. T. (2010). Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid. Redox Signal. 13, 1713-1748.
17. Imamura, H., Nhat, K. P., Togawa, H., Saito, K., Iino, R., Kato-Yamada, Y., Nagai, T. and Noji, H. (2009). Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. Proc. Natl. Acad. Sci. USA 106, 15651-15656.
18. Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I. et al. (1997). An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236, 313-322.
19. Kensler, T. W., Wakabayashi, N. and Biswal, S. (2007). Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89-116.
20. Kensler, T. W., Egner, P. A., Agyeman, A. S., Visvanathan, K., Groopman, J. D., Chen, J. G., Chen, T. Y., Fahey, J. W. and Talalay, P. (2013). Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane. Top. Curr. Chem. 329, 163-177.
21. Kim, T. H., Hur, E. G., Kang, S. J., Kim, J. A., Thapa, D., Lee, Y. M., Ku, S. K., Jung, Y. and Kwak, M. K. (2011). NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1a. Cancer Res. 71, 2260-2275.
22. Kirby, J., Halligan, E., Baptista, M. J., Allen, S., Heath, P. R., Holden, H., Barber, S. C., Loynes, C. A., Wood-Allum, C. A., Lunec, J. et al. (2005). Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain 128, 1686-1706.
23. Lee, J. M., Calkins, M. J., Chan, K., Kan, Y. W. and Johnson, J. A. (2003a). Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J. Biol. Chem. 278, 12029-12038.
24. Lee, J. M., Shih, A. Y., Murphy, T. H. and Johnson, J. A. (2003b). NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J. Biol. Chem. 278, 37948-37956.
25. Liby, K. T. and Sporn, M. B. (2012). Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol. Rev. 64, 972-1003.
26. MacDonald, M. J. and Marshall, L. K. (2001). Survey of normal appearing mouse strain which lacks malic enzyme and Nad+-linked glycerol phosphate dehydrogenase: normal pancreatic beta cell function, but abnormal metabolite pattern in skeletal muscle. Mol. Cell. Biochem. 220, 117-125.
27. Malhotra, D., Portales-Casamar, E., Singh, A., Srivastava, S., Arenillas, D., Happel, C., Shyr, C., Wakabayashi, N., Kensler, T. W., Wasserman, W. W. et al. (2010). Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 38, 5718-5734.
28. Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M. and Motohashi, H. (2012). Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22, 66-79.
29. Nguyen, T., Nioi, P. and Pickett, C. B. (2009). The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284, 13291-13295.
30. Pergola, P. E., Krauth, M., Huff, J. W., Ferguson, D. A., Ruiz, S., Meyer, C. J. and Warnock, D. G. (2011a). Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am. J. Nephrol. 33, 469-476.
31. Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H. et al.; BEAM Study Investigators. (2011b). Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327-336.
32. Prochaska, H. J. and Santamaria, A. B. (1988). Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal. Biochem. 169, 328-336.
33. Rice, G. C., Bump, E. A., Shrieve, D. C., Lee, W. and Kovacs, M. (1986). Quantitative analysis of cellular glutathione by flow cytometry utilizing monochlorobimane: some applications to radiation and drug resistance in vitro and in vivo. Cancer Res. 46, 6105-6110.
34. Schuit, F. C., Huypens, P., Heimberg, H. and Pipeleers, D. G. (2001). Glucose sensing in pancreatic beta-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus. Diabetes 50, 1-11.
35. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J. and Klenk, D. C. (1985). Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85.
36. Taguchi, K., Maher, J. M., Suzuki, T., Kawatani, Y., Motohashi, H. and Yamamoto, M. (2010). Genetic analysis of cytoprotective functions supported by graded expression of Keap1. Mol. Cell. Biol. 30, 3016-3026.
37. Talalay, P. (2000). Chemoprotection against cancer by induction of phase 2 enzymes. Biofactors 12, 5-11.
38. Thimmulappa, R. K., Mai, K. H., Srisuma, S., Kensler, T. W., Yamamoto, M. and Biswal, S. (2002). Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62, 5196-5203.
39. Vaarmann, A., Gandhi, S., Gourine, A. V. and Abramov, A. Y. (2010). Novel pathway for an old neurotransmitter: dopamine-induced neuronal calcium signalling via receptor-independent mechanisms. Cell Calcium 48, 176-182.
40. Wakabayashi, N., Itoh, K., Wakabayashi, J., Motohashi, H., Noda, S., Takahashi, S., Imakado, S., Kotsuji, T., Otsuka, F., Roop, D. R. et al. (2003). Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 35, 238-245.
41. Wang, G. J., Randall, R. D. and Thayer, S. A. (1994). Glutamate-induced intracellular acidification of cultured hippocampal neurons demonstrates altered energy metabolism resulting from Ca2+ loads. J. Neurophysiol. 72, 2563-2569.
42. Warburg, O. (1956). On the origin of cancer cells. Science 123, 309-314.
43. Wittig, I., Braun, H. P. and Schägger, H. (2006). Blue native PAGE. Nat. Protoc. 1, 418-428.
44. Wu, K. C., Cui, J. Y. and Klaassen, C. D. (2011). Beneficial role of Nrf2 in regulating NADPH generation and consumption. Toxicol. Sci. 123, 590-600.
45. Yao, Z., Gandhi, S., Burchell, V. S., Plun-Favreau, H., Wood, N. W. and Abramov, A. Y. (2011). Cell metabolism affects selective vulnerability in PINK1-associated Parkinson's disease. J. Cell Sci. 124, 4194-4202.
46. Zheng, H., Whitman, S. A., Wu, W., Wondrak, G. T., Wong, P. K., Fang, D. and Zhang, D. D. (2011). Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60, 3055-3066.